American Society of Clinical Oncology .28ASCO.29 Annual Meeting 1999 High-dose chemotherapy and bone marrow transplant




william peters presented preliminary results calgb study (fully described calgb 9082/swog 9114/ncic ma-13). peters found no significant difference in either event-free or overall survival between randomized groups. there 31 deaths related therapy in high-dose arm; rate of 7.4%. study design called additional 3 years of follow-up before final conclusions drawn.


the scandinavian breast cancer study group 9401 randomised 525 high risk breast cancer patients between march 1, 1994 march 4, 1998. principal investigator jonas bergh reported no overall survival benefit high-dose therapy versus tailored regimen, after median follow-up time of 27 months.


finally, werner bezwoda presented randomised, controlled clinical trial of 154 patients. majority of patients black, , under age 55. study differed others in no induction therapy used; patients randomized either high-dose or standard therapy. after 5 years, 21 of 75 patients on high-dose arm had relapsed, compared 55 of 79 patients on standard dose arm. relapse-free survival , overall survival better in high-dose arm.



high-dose chemotherapy using cmvp combination found able given safely younger patients high-risk breast cancer. high-dose chemotherapy resulted in low relapse rate, , high-dose chemotherapy associated longer disease-free , overall survival in patient population.










Comments

Popular posts from this blog

Gigantomastia Breast hypertrophy

Release information Conversations with Other Women

Operation Unified Task Force